임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
18건 표시
- 4상모집 중· Coronary Artery DiseaseComparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization
협력: 한미약품, 유한양행
- 4상상태 미확인· Breast NeoplasmsReducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy
협력: 한미약품
- 4상모집 중· Coronary Artery DiseaseHarmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
협력: 대웅제약, 한미약품, 유한양행
- 4상상태 미확인· Acute Upper Respiratory InfectionClinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase)
리드: 한미약품
- 4상상태 미확인· Erectile DysfunctionEffect of Tadalafil on Erectile Dysfunction Treatment and QOL Improvement Effect (by SF-12) in Andropause Patients With Erectile Dysfunction
협력: 한미약품
- 4상완료· Hepatocellular CarcinomaThe Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction
협력: 한미약품
- 4상상태 미확인· Mild Cognitive ImpairmentEvaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease
리드: 한미약품
- 4상상태 미확인· Chronic Hepatitis BStudy to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude
리드: 한미약품
- 4상완료· Coronary Heart DiseaseHarmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)
협력: 종근당, 대웅제약, 한미약품
- 4상상태 미확인· Chronic Kidney DiseaseEfficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia
리드: 한미약품
- 4상완료· Coronary Artery DiseaseKorean Multicenter Randomized Controlled Trial (RCT) of Pidogul for Patients With Coronary Stenting
협력: 한미약품
- 4상완료· Coronary Artery Disease (CAD)Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients
리드: 한미약품
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.